Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

(2018) Robert M. Jotte et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).

(2018) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma

(2017) Paola Claudia Sacco et al.   EXPERT OPINION ON EMERGING DRUGS

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

(2017) C Hardin et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

(2017) Eisaku Miyauchi et al.   ONCOLOGIST

Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons

(2017) Mitsunori Higuchi et al.   Oncology Letters

Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments

(2017) Jianchun Duan et al.   Thoracic Cancer

Non–Small Cell Lung Cancer

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer

(2017) Yi Chen et al.   Scientific Reports

A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer

(2016) Yusuke Okuma et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

(2016) Kyoichi Kaira et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes

(2016) Vera Hirsh et al.   Clinical Lung Cancer

Phase II trial of weekly nab-paclitaxel for previously treated advanced non–small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301

(2016) Shinya Sakata et al.   LUNG CANCER

Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent

(2016) Ashish Saxena et al.   MEDICAL ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer

(2016) Kazutoshi Komiya et al.   OncoTargets and Therapy

Survival, quality-adjusted survival and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

(2015) C J Langer et al.   BRITISH JOURNAL OF CANCER

Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients

(2015) Erin M. Bertino et al.   Clinical Lung Cancer

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment

(2015) Corey J. Langer et al.   Clinical Lung Cancer

Metabolism of the taxanes including nab-paclitaxel

(2014) Markus Joerger   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics and pharmacodynamics ofnab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel

(2014) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Unraveling the mysteries of serum albumin—more than just a serum protein

(2014) Angelica M. Merlot et al.   Frontiers in Physiology

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

(2013) M. A. Socinski et al.   ANNALS OF ONCOLOGY

Treatment of Stage IV Non-small Cell Lung Cancer

(2013) Mark A. Socinski et al.   CHEST

Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer

(2013) Vera Hirsh et al.   Journal of Thoracic Oncology

Safety and efficacy of weekly nab(R)-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

(2012) M. A. Socinski et al.   ANNALS OF ONCOLOGY

Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology

(2012) Mark N. Levine et al.   JOURNAL OF CLINICAL ONCOLOGY

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemical proteomics: terra incognita for novel drug target profiling

(2012) Fuqiang Huang et al.   Chinese Journal of Cancer

Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?

(2011) Corey J. Langer   Clinical Lung Cancer

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer

(2011) Huanjie Shao et al.   Journal of Thoracic Oncology

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

(2010) Xin-Sheng Lai et al.   CURRENT DRUG METABOLISM

Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Amy J. Davidoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

(2010) Craig Reynolds et al.   Journal of Thoracic Oncology

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

(2010) Mark A. Socinski et al.   Journal of Thoracic Oncology

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

(2009) David R. Gandara et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

(2008) E. R. Gardner et al.   CLINICAL CANCER RESEARCH

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

(2008) Chandra P. Belani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

(2008) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

(2008) Filippo de Marinis et al.   Journal of Thoracic Oncology